Compare HTFL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTFL | PHVS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2025 | 2020 |
| Metric | HTFL | PHVS |
|---|---|---|
| Price | $46.80 | $32.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $65.00 | $58.05 |
| AVG Volume (30 Days) | ★ 1.7M | 540.9K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,034,000.00 | N/A |
| Revenue This Year | $49.74 | N/A |
| Revenue Next Year | $24.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.92 | N/A |
| 52 Week Low | $20.13 | $23.15 |
| 52 Week High | $60.66 | $43.25 |
| Indicator | HTFL | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 44.47 |
| Support Level | $46.46 | $25.67 |
| Resistance Level | $52.38 | $36.14 |
| Average True Range (ATR) | 3.76 | 1.59 |
| MACD | -1.33 | -0.09 |
| Stochastic Oscillator | 5.25 | 16.99 |
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.